Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC von Bauer, Todd M., Besse, Benjamin, Martinez-Marti, Alex, Trigo, Jose Manuel, Moreno, Victor, Garrido, Pilar, Ferron-Brady, Geraldine, Wu, Yuehui, Park, Jennifer, Collingwood, Therese, Kruger, Ryan G., Mohammad, Helai P., Ballas, Marc S., Dhar, Arindam, Govindan, Ramaswamy

Volltext

A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN von Komiya, Takefumi, Blumenthal, Gideon M., DeChowdhury, Roopa, Fioravanti, Susan, Ballas, Marc S., Morris, John, Hornyak, Thomas J., Wank, Stephen, Hewitt, Stephen M., Morrow, Betsy, Memmott, Regan M., Rajan, Arun, Dennis, Phillip A.

Volltext

Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas von Karajannis, Matthias A, Legault, Geneviève, Hagiwara, Mari, Ballas, Marc S, Brown, Krysten, Nusbaum, Annette O, Hochman, Tsivia, Goldberg, Judith D, Koch, Kevin M, Golfinos, John G, Roland, J Thomas, Allen, Jeffrey C

Volltext

A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer von Camidge, D. Ross, Berge, Eamon M., Doebele, Robert C., Ballas, Marc S., Jahan, Thierry, Haigentz, Missak, Hoffman, David, Spicer, James, West, Howard, Lee, Pablo, Yang, Ling, Joshi, Adarsh, Gao, Ling, Yurasov, Sergey, Mita, Alain

Volltext

Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC von Ballas, Marc S, Chachoua, Abraham

Volltext

A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors von Blumenthal, Gideon M, Gills, Joell J, Ballas, Marc S, Bernstein, Wendy B, Komiya, Takefumi, Dechowdhury, Roopa, Morrow, Betsy, Root, Hyejeong, Chun, Guinevere, Helsabeck, Cynthia, Steinberg, Seth M, LoPiccolo, Jaclyn, Kawabata, Shigeru, Gardner, Erin R, Figg, William D, Dennis, Phillip A

Volltext

A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer von Komiya, Takefumi, Memmott, Regan M., Blumenthal, Gideon M., Bernstein, Wendy, Ballas, Marc S., De Chowdhury, Roopa, Chun, Guinevere, Peer, Cody J., Figg, William D., Liewehr, David J., Steinberg, Seth M., Giaccone, Giuseppe, Szabo, Eva, Kawabata, Shigeru, Tsurutani, Junji, Rajan, Arun, Dennis, Phillip A.

Volltext

A Phase II Study of Halichondrin B Analog Eribulin Mesylate (E7389) in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with a Taxane: A California Cancer Conso... von Gitlitz, Barbara J., Tsao-Wei, Denice D., Groshen, Susan, Davies, Angela, Koczywas, Marianna, Belani, Chandra P., Argiris, Athanassios, Ramalingam, Suresh, Vokes, Everett E., Edelman, Martin, Hoffman, Philip, Ballas, Marc S., Liu, Stephen V., Gandara, David R.

Volltext

A slow disengagement from platinum-based chemotherapy for patients with advanced non-small cell lung cancer von Ballas, Marc S., Dennis, Phillip A.

Volltext

PTEN hamartomatous tumor syndromes (PHTS): Rare syndromes with great relevance to common cancers and targeted drug development von LoPiccolo, Jaclyn, Ballas, Marc S, Dennis, Phillip A

Volltext

Overestimating the influence of the 1999 WHO classification of lung tumors on survival in bronchioloalveloar carcinoma von Tsurutani, Junji, Ballas, Marc S, Dennis, Phillip A

Volltext

Real-world immuno-oncology treatment patterns and outcomes in US patients with metastatic non-small-cell lung cancer von Bruno, Amanda, Bell, Kelly, Stafkey-Mailey, Dana, Murty, Sharanya, Ballas, Marc S.

Volltext

Evolution of standard of care therapies used for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A real-world analysis of patient health records from 201... von Saba, Nabil F., Shukla, Soham, Aguilar, Kathleen M., Ballas, Marc S., Bell, Kelly, Boyd, Marley, Chao, Jessica, Ellis, Catherine Elizabeth, Phiri, Kelesitse, Tseng, Wan-Yu, Nadler, Eric S.

Volltext

Inducible T-cell co-stimulatory (ICOS) receptor agonist, feladilimab (fela), alone and in combination (combo) with pembrolizumab (P): Results from INDUCE-1 urothelial carcinoma (UC... von Balar, Arjun Vasant, Moreno, Victor, Angevin, Eric, Gan, Hui Kong, Vieito, Maria, Italiano, Antoine, Danielli, Riccardo, Massarelli, Erminia, Opdam, Frans, Chisamore, Michael Jon, Rogan, Debra, Ji, Xiao, Henry, Courtney, Ellis, Catherine Elizabeth, Ballas, Marc S., Hoos, Axel, Ricci, Francesco

Volltext

DREAMM-5 platform trial: Belantamab mafodotin in combination with novel agents in patients with relapsed/refractory multiple myeloma (RRMM) von Richardson, Paul G., Biswas, Swethajit, Holkova, Beata, Jackson, Nicola, Netherway, Thelma, Paul, Sofia, Ferron-Brady, Geraldine, Yeakey, Anne, Shelton, Chris, Montes de Oca, Rocio, Ahlers, Christoph Matthias, Ballas, Marc S., Paul, Elaine Marie, Gupta, Ira, Opalinska, Joanna, Luptakova, Katarina

Volltext

DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refra... von Callander, Natalie S., Ribrag, Vincent, Richardson, Paul G., Nooka, Ajay K., Song, Kevin, Uttervall, Katarina, Minnema, Monique C., Weisel, Katja, Quach, Hang, Min, Chang-Ki, Ballas, Marc S., Li, Xiaofang, Ratia, Nirav, Kaisermann, Morrys, Holkova, Beata, Trudel, Suzanne

Volltext

Updated analysis of the inducible T-cell co-stimulatory receptor (ICOS) agonist, GSK3359609 (GSK609), combination with pembrolizumab (PE) in patients (pts) with anti-PD-1/L1 treatm... von Angevin, Eric, Groenland, Stefanie L., Lim, Annette May Ling, Martin-Liberal, Juan, Moreno, Victor, Trigo, Jose Manuel, Le Tourneau, Christophe, Mathew, Matthen, Cho, Daniel C., Hansen, Aaron Richard, Vicente, David, Maio, Michele, Italiano, Antoine, Bauman, Jessica Ruth, Chisamore, Michael Jon, Zhou, Helen, Ellis, Catherine Elizabeth, Ballas, Marc S., Hoos, Axel, Rischin, Danny

Volltext

INDUCE-3: A randomized, double-blind study of GSK3359609 (GSK609), an inducible T-cell co-stimulatory (ICOS) agonist antibody, plus pembrolizumab (PE) versus placebo (PL) plus PE f... von Hansen, Aaron Richard, Stanton, Thomas S., Hong, Min Hee, Cohen, Ezra E.W., Mehanna, Hisham Mohamed, Chisamore, Michael Jon, Turner, David, Yadavilli, Sapna, Bell, Kelly, Baccan, Carlos, Leone, Rosalida, Chen, Helen, Zhou, Helen, Ellis, Catherine Elizabeth, Ballas, Marc S., Hoos, Axel, Rischin, Danny

Volltext

INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5-FU chemotherapy (5-FU/plat), with or... von Massarelli, Erminia, Balmanoukian, Ani Sarkis, Vieito, Maria, Le Tourneau, Christophe, Hernandez-Guerrero, Tatiana, Trigo, Jose Manuel, Aljumaily, Raid, Chisamore, Michael Jon, Rogan, Debra, Sung, Ruby, Henry, Courtney, Turner, David, Yadavilli, Sapna, Franco, Sonia, Ellis, Catherine Elizabeth, Ballas, Marc S., Hoos, Axel, Rischin, Danny

Volltext

A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in... von Sparano, Joseph A., Cescon, David W., Oliveira, Mafalda, Stover, Daniel G., Tan-Chiu, Elizabeth, Kremer, Brandon Edward, Barbash, Olena, Wu, Yuehui, Mathew, Lijoy, Cunningham, Elizabeth Ann, Carpenter, Christopher L., Ballas, Marc S., Dhar, Arindam

Volltext